Table of Content


1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights


2. Assumptions and Research Methodology


3. Executive Summary: Global Neurological Disorder Drugs Market


4. Market Overview

4.1. Introduction & Overview

4.2. Product Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Neurological Disorder Drugs Market Analysis and Forecast, 2017–2027


5. Market Outlook

5.1. Pipeline Analysis

5.2. Disease Prevalence & Incidence Rate globally with key countries

5.3. Regulatory Scenario


6. Global Neurological Disorder Drugs Market Analysis and Forecast, by Disorder

6.1. Introduction & Definition

6.2. Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

6.2.1. Epilepsy

6.2.2. Alzheimer Disease

6.2.3. Multiple Sclerosis

6.2.4. Parkinson Disease

6.2.5. Cerebrovascular Diseases

6.2.6. Others

6.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder


7. Global Neurological Disorder Drugs Market Analysis and Forecast, by Drug Class

7.1. Introduction & Definition

7.2. Global Neurological Disorder Drugs Market Value (US$) Forecast, by Drug Class, 2017–2027

7.2.1. Anticholinergic

7.2.2. Antiepileptic

7.2.3. Antipsychotic

7.2.4. Analgesic

7.2.5. Hypnotic & Sedative

7.2.6. Antihypertensive

7.2.7. Anticoagulants

7.2.8. Others

7.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class


8. Global Neurological Disorder Drugs Market Analysis and Forecast, by Distribution Channel

8.1. Introduction & Definition

8.2. Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

8.2.1. Hospital Pharmacies

8.2.2. Retail Pharmacies

8.2.3. Online Pharmacies

8.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel


9. Global Neurological Disorder Drugs Market Analysis and Forecast, by Region

9.1. Key Findings

9.2. Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Region

9.2.1. North America

9.2.2. Europe

9.2.3. Asia Pacific

9.2.4. Latin America

9.2.5. Middle East & Africa

9.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Region


10. North America Neurological Disorder Drugs Market Analysis and Forecast

10.1. Introduction

10.2. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

10.2.1. Epilepsy

10.2.2. Alzheimer Disease

10.2.3. Multiple Sclerosis

10.2.4. Parkinson Disease

10.2.5. Cerebrovascular Diseases

10.2.6. Others

10.3. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

10.3.1. Anticholinergic

10.3.2. Antiepileptic

10.3.3. Antipsychotic

10.3.4. Analgesic

10.3.5. Hypnotic & Sedative

10.3.6. Antihypertensive

10.3.7. Anticoagulants

10.3.8. Others

10.4. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

10.4.1. Hospital Pharmacies

10.4.2. Retail Pharmacies

10.4.3. Online Pharmacies

10.5. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

10.5.1. U.S.

10.5.2. Canada

10.6. North America Neurological Disorder Drugs Market Attractiveness Analysis

10.6.1. By Disorder

10.6.2. By Drug Class

10.6.3. By Distribution Channel

10.6.4. By Country


11. Europe Neurological Disorder Drugs Market Analysis and Forecast

11.1. Introduction

11.2. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

11.2.1. Epilepsy

11.2.2. Alzheimer Disease

11.2.3. Multiple Sclerosis

11.2.4. Parkinson Disease

11.2.5. Cerebrovascular Diseases

11.2.6. Others

11.3. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

11.3.1. Anticholinergic

11.3.2. Antiepileptic

11.3.3. Antipsychotic

11.3.4. Analgesic

11.3.5. Hypnotic & Sedative

11.3.6. Antihypertensive

11.3.7. Anticoagulants

11.3.8. Others

11.4. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

11.4.1. Hospital Pharmacies

11.4.2. Retail Pharmacies

11.4.3. Online Pharmacies

11.5. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

11.5.1. Germany

11.5.2. U.K.

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Rest of Europe

11.6. Europe Neurological Disorder Drugs Market Attractiveness Analysis

11.6.1. By Disorder

11.6.2. By Drug Class

11.6.3. By Distribution Channel

11.6.4. By Country/Sub-region

12. Asia Pacific Neurological Disorder Drugs Market Analysis and Forecast

12.1. Introduction

12.2. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

12.2.1. Epilepsy

12.2.2. Alzheimer Disease

12.2.3. Multiple Sclerosis

12.2.4. Parkinson Disease

12.2.5. Cerebrovascular Diseases

12.2.6. Others

12.3. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

12.3.1. Anticholinergic

12.3.2. Antiepileptic

12.3.3. Antipsychotic

12.3.4. Analgesic

12.3.5. Hypnotic & Sedative

12.3.6. Antihypertensive

12.3.7. Anticoagulants

12.3.8. Others

12.4. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

12.4.1. Hospital Pharmacies

12.4.2. Retail Pharmacies

12.4.3. Online Pharmacies

12.5. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

12.5.1. China

12.5.2. Japan

12.5.3. India

12.5.4. Australia & New Zealand

12.5.5. Rest of Asia Pacific

12.6. Asia Pacific Neurological Disorder Drugs Market Attractiveness Analysis

12.6.1. By Disorder

12.6.2. By Drug Class

12.6.3. By Distribution Channel

12.6.4. By Country/Sub-region

13. Latin America Neurological Disorder Drugs Market Analysis and Forecast

13.1. Introduction

13.2. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

13.2.1. Epilepsy

13.2.2. Alzheimer Disease

13.2.3. Multiple Sclerosis

13.2.4. Parkinson Disease

13.2.5. Cerebrovascular Diseases

13.2.6. Others

13.3. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

13.3.1. Anticholinergic

13.3.2. Antiepileptic

13.3.3. Antipsychotic

13.3.4. Analgesic

13.3.5. Hypnotic & Sedative

13.3.6. Antihypertensive

13.3.7. Anticoagulants

13.3.8. Others

13.4. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

13.4.1. Hospital Pharmacies

13.4.2. Retail Pharmacies

13.4.3. Online Pharmacies

13.5. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

13.5.1. Brazil

13.5.2. Mexico

13.5.3. Rest of Latin America

13.6. Latin America Neurological Disorder Drugs Market Attractiveness Analysis

13.6.1. By Disorder

13.6.2. By Drug Class

13.6.3. By Distribution Channel

13.6.4. By Country/Sub-region


14. Middle East & Africa Neurological Disorder Drugs Market Analysis and Forecast

14.1. Introduction

14.2. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

14.2.1. Epilepsy

14.2.2. Alzheimer Disease

14.2.3. Multiple Sclerosis

14.2.4. Parkinson Disease

14.2.5. Cerebrovascular Diseases

14.2.6. Others

14.3. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

14.3.1. Anticholinergic

14.3.2. Antiepileptic

14.3.3. Antipsychotic

14.3.4. Analgesic

14.3.5. Hypnotic & Sedative

14.3.6. Antihypertensive

14.3.7. Anticoagulants

14.3.8. Others

14.4. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

14.4.1. Hospital Pharmacies

14.4.2. Retail Pharmacies

14.4.3. Online Pharmacies

14.5. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

14.5.1. GCC Countries

14.5.2. South Africa

14.5.3. Rest of Middle East & Africa

14.6. Middle East & Africa Neurological Disorder Drugs Market Attractiveness Analysis

14.6.1. By Disorder

14.6.2. By Drug Class

14.6.3. By Distribution Channel

14.6.4. By Country/Sub-region


15. Competition Landscape

15.1. Competition Matrix

15.2. Market Share Analysis, by Company, 2018

15.3. Company Profiles

15.3.1. Novartis AG

15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.1.2. Company Financials

15.3.1.3. Growth Strategies

15.3.1.4. SWOT Analysis

15.3.2. GlaxoSmithKline plc

15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.2.2. Company Financials

15.3.2.3. Growth Strategies

15.3.2.4. SWOT Analysis

15.3.3. F. Hoffmann-La Roche Ltd.

15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.3.2. Company Financials

15.3.3.3. Growth Strategies

15.3.3.4. SWOT Analysis

15.3.4. Pfizer, Inc.

15.3.4.1. Company Overview (HQ, Business Segments)

15.3.4.2. Company Financials

15.3.4.3. Growth Strategies

15.3.4.4. SWOT Analysis

15.3.5. Bayer AG

15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.5.2. Company Financials

15.3.5.3. Growth Strategies

15.3.5.4. SWOT Analysis

15.3.6. Boehringer Ingelheim International GmbH

15.3.6.1. Company Overview (HQ, Business Segments)

15.3.6.2. Company Financials

15.3.6.3. Growth Strategies

15.3.6.4. SWOT Analysis

15.3.7. AstraZeneca plc

15.3.7.1. Company Overview (HQ, Business Segments)

15.3.7.2. Company Financials

15.3.7.3. Growth Strategies

15.3.7.4. SWOT Analysis

15.3.8. Teva Pharmaceutical Industries Ltd.

15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.8.2. Company Financials

15.3.8.3. Growth Strategies

15.3.8.4. SWOT Analysis

15.3.9. Merck & Co., Inc.

15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.9.2. Company Financials

15.3.9.3. Growth Strategies

15.3.9.4. SWOT Analysis

15.3.10. Otsuka Pharmaceutical Co., Ltd.

15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.10.2. Company Financials

15.3.10.3. Growth Strategies

15.3.10.4. SWOT Analysis

15.3.11. Amgen, Inc.

15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.11.2. Company Financials

15.3.11.3. Growth Strategies

15.3.11.4. SWOT Analysis

15.3.12. UCB S.A.

15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.12.2. Company Financials

15.3.12.3. Growth Strategies

15.3.12.4. SWOT Analysis

15.3.13. Eli Lilly and Company

15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.13.2. Company Financials

15.3.13.3. Growth Strategies

15.3.13.4. SWOT Analysis

15.3.14. Biogen

15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.14.2. Company Financials

15.3.14.3. Growth Strategies

15.3.14.4. SWOT Analysis



List of Figures




Figure 01: Global Neurological Disorder Drugs Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027

Figure 02: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, 2017–2027

Figure 03: Global Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027

Figure 04: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Epilepsy, 2017–2027

Figure 05: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Alzheimer’s Disease, 2017–2027

Figure 06: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Parkinson’s Disease, 2017–2027

Figure 07: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Multiple Sclerosis, 2017–2027

Figure 08: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cerebrovascular Diseases, 2017–2027

Figure 09: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 10: Global Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019–2027

Figure 11: Global Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 12: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anticholinergic, 2017–2027

Figure 13: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antiepileptic, 2017–2027

Figure 14: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antipsychotic, 2017–2027

Figure 15: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Analgesic, 2017–2027

Figure 16: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hypnotic & Sedative, 2017–2027

Figure 17: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antihypertensive, 2017–2027

Figure 18: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anticoagulant, 2017–2027

Figure 19: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 20: Global Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 21: Global Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 22: Global Neurological Disorder Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Retail Pharmacies, 2017–2027

Figure 23: Global Neurological Disorder Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacies, 2017–2027

Figure 24: Global Neurological Disorder Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacies, 2017–2027

Figure 25: Global Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 26: Global Neurological Disorder Drugs Market, by Region, 2018 and 2027

Figure 27: Global Neurological Disorder Drugs Market Attractiveness Analysis, by Region, 2019–2027

Figure 28: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 29: North America Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027

Figure 30: North America Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019–2027

Figure 31: North America Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 32: North America Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 33: North America Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 34: North America Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 35: North America Neurological Disorder Drugs Market Value Share Analysis, by Country, 2018 and 2027

Figure 36: North America Neurological Disorder Drugs Market Attractiveness Analysis, by Country, 2019–2027

Figure 37: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 38: Europe Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027

Figure 39: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019–2027

Figure 40: Europe Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 41: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 42: Europe Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 43: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 44: Europe Neurological Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 45: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 46: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 47: Asia Pacific Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027

Figure 48: Asia Pacific Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019–2027

Figure 49: Asia Pacific Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 50: Asia Pacific Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 51: Asia Pacific Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 52: Asia Pacific Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 53: Asia Pacific Neurological Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 54: Asia Pacific Neurological Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 55: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 56: Latin America Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027

Figure 57: Latin America Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019–2027

Figure 58: Latin America Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 59: Latin America Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 60: Latin America Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 61: Latin America Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 62: Latin America Neurological Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 63: Latin America Neurological Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 64: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 65: Middle East & Africa Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027

Figure 66: Middle East & Africa Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019–2027

Figure 67: Middle East & Africa Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 68: Middle East & Africa Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 69: Middle East & Africa Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 70: Middle East & Africa Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 71: Middle East & Africa Neurological Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 72: Middle East & Africa Neurological Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027


List of Tables




Table 01: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 02: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 03: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 04: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 05: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 06: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 07: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 08: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 09: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 10: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 11: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 12: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 13: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 14: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 15: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 16: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 17: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 18: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 19: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 20: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 21: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 22: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 23: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 24: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027